The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

NCT07152340 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Associated Ophthalmopathies

Interventions

DRUG: IBI311
DRUG: Glucocorticoids

Sponsor

Shanghai Changzheng Hospital